UN Sustainable Development Goals

Our Action: We make life better for more than 58 million people around the world who use Lilly medicines. Through investments in people, medicines and health systems, we also aim to reach 30 million people in resource-limited settings annually by 2030. Additionally, in accordance with the Doha Declaration on the TRIPS Agreement, Lilly doesn't pursue or enforce patents in the least developed countries.

U.S. Access & Affordability, Global Access & Health, Community Engagement, Patient Safety, Employee Experience

Our Action: We're committed to improving educational opportunities for children living in underserved communities in Indianapolis. Lilly and the Lilly Foundation focus on early childhood education, supporting quality schools and STEM (science, technology, engineering and math) education.

Community Engagement

Our Action: We continue to build a dynamic and inclusive company by embedding inclusion into our leadership, systems and culture. It is core to our business success because it fosters innovation and allows us to connect more closely with our customers.

Inclusion, Employee Experience, Human Rights

Our Action: Water is a critical resource that Lilly is committed to using wisely. We continue to assess our water risks as we focus on conserving water, reducing our intake and improving water quality. One-hundred percent of Lilly sites will meet predicted no-effect concentrations (PNEC) for Pharmaceuticals in the Environment by 2030.

Water, Waste

Our Action: By 2030, 100% of purchased electricity at Lilly will come from renewable sources and we will be carbon neutral in our own operations (Scope 1 and 2 emissions). Additionally, we're enhancing the tracking and reporting of greenhouse gas emissions across our value chain.

Climate

Our Action: At Lilly, we're committed to maintaining a safe workplace and providing opportunities for employees to learn and develop. We also believe that doing business with a varied set of suppliers helps the company accelerate innovation and deliver strong results. In 2024, we spent about $1.3 billion with approximately 1,300 suppliers classified as small businesses.

Employee Experience, Supply Chain Management,

Our action: We’re partnering with industry peers and other organizations with proven track records to improve global health, including through improved NCD care for children and adolescents and supporting community health workers in Africa. We also work with leading disaster relief organizations to provide medicines and support people and communities to help them recover.

U.S. Access & Affordability, Global Access & Health, Community Engagement

Our Action: We are committed to addressing complex health challenge around the world, including a focus on noncommunicable diseases and people living in resource-limited communities in the U.S. and low- and middle-income countries. We are committed to expanding equitable and affordable access to our breakthrough medicines so that they can transform more people’s lives. Additionally, we are committed to pay equity for all employees in our workforce. We conduct pay equity studies on our workforce globally and believe that pay equity is critical to our success in supporting a global and inclusive workforce.

U.S. Access & Affordability, Global Access & Health, Community Engagement

Our Action: We optimize the fuel efficiency and reduce the GHG emissions generated by our sales force fleet by choosing vehicles with better fuel economy, and promoting driving and work practices that emphasize safety and fuel savings. We strive for energy efficiency and the use of renewable electricity to support our operations.

Climate

Our Action: We strive to embed environmental innovation early in the product development lifecycle through our focus on green chemistry and end-product engineering. By 2030, 100% of plastic waste is expected to be repurposed for beneficial use, with at least 90% recycled or reused, and zero waste to landfill from routine operations.

Waste, Product Stewardship,

Our Action: By 2030, 100% of purchased electricity at Lilly is expected to come from renewable sources and we will be carbon neutral in our own operations (Scope 1 and 2 emissions). Additionally, we're enhancing the tracking and reporting of greenhouse gas emissions across our value chain.

Climate

Our Action: Lilly continues to be an industry leader in using rFC, a scientifically proven, sustainable alternative to the horseshoe crab-sourced testing reagent, LAL. This is especially important given that several species of crabs are under threat or endangered from habitat loss and overharvesting.

Water, Product Stewardship, Biodiversity

Our Action: We strive to protect designated biodiversity rich areas, manage existing biodiversity at our sites and enhance biodiversity within the communities where we operate.

Biodiversity

Our Action: We train all of our employees in ethical business practices and have systems in place to detect violations of laws, regulations and company policies, including those related to anti-corruption. We also expect our vendors to abide by Lilly’s human rights standards and our Supplier Code of Business Conduct.

Business Ethics, Corporate Governance, Human Rights

Our Action: Through strategic partnerships, Lilly and the Eli Lilly and Company Foundation work to advance government priorities, strengthen local health care systems and improve access to care. Lilly also establishes key partnerships to extend the reach of our impact and engage in targeted social issues that affect our business and employees, with an emphasis on economic health and education.

U.S. Access & Affordability, Global Access & Health, Community Engagement